skip to content »

Section of Atherosclerosis

Houston, Texas

BCM faculty, staff and trainees are the heart of the organization.
Section of Atherosclerosis and Vascular Medicine
not shown on screen

Publications 2009

  1. Yang EY, Nambi V, Tang Z, Virani SS, Boerwinkle E, Hoogeveen RC, Astor BC, Mosley TH, Coresh J, Chambless L, Ballantyne CM. Clinical implications of JUPITER (Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) in a U.S. population insights from the ARIC (Atherosclerosis Risk in Communities) study. J Am Coll Cardiol 2009;54:2388-2395.
  2. Virani SS, Nambi V, Lee VV, Elayda MA, Pan W, Petersen LA, Wilson JM, Willerson JT, Ballantyne CM. Obesity: an independent predictor of in-hospital postoperative renal insufficiency among patients undergoing cardiac surgery? Tex Heart Inst J 2009;36:540-545.
  3. Schnabel RB, Baumert J, Barbalic M, Dupuis J, Ellinor PT, Durda P, Dehghan A, Bis JC, Illig T, Morrison AC, Jenny NS, Keaney JF Jr, Gieger C, Tilley C, Yamamoto JF, Khuseyinova N, Heiss G, Doyle M, Blankenberg S, Herder C, Walston JD, Zhu Y, Vasan RS, Klopp N, Boerwinkle E, Larson MG, Psaty BM, Peters A, Ballantyne CM, Witteman JC, Hoogeveen RC, Benjamin EJ, Koenig W, Tracy RP. Duffy antigen receptor for chemokines (Darc) polymorphism regulates circulating concentrations of monocyte chemoattractant protein-1 and other inflammatory mediators. Blood 2009. [Epub ahead of print]
  4. Brautbar A, Ballantyne CM, Lawson K, Nambi V, Chambless L, Folsom AR, Willerson JT, Boerwinkle E. Impact of adding a single allele in the 9p21 locus to traditional risk factors on reclassification of coronary heart disease risk and implications for lipid-modifying therapy in the Atherosclerosis Risk in Communities study. Circ Cardiovasc Genet 2009;2:279-285.
  5. Schwartz GG, Olsson AG, Ballantyne CM, Barter PJ, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Shah PK, Tardif JC, Chaitman BR, Duttlinger-Maddux R, Mathieson J; dal-OUTCOMES Committees and Investigators. Ration ale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. Am Heart J 2009;158:896-901.
  6. Bang H, Edwards AM, Bomback AS, Ballantyne CM, Brillon D, Callahan MA, Teutsch SM, Mushlin AI, Kern LM. Develo pment and validation of a patient self-assessment score for diabetes risk. Ann Intern Med 2009;151:775-783.
  7. Polis AB, Abate N, Catapano AL, Ballantyne CM, Davidson MH, Smugar SS, Tershakovec AM. Low-d ensity lipoprotein cholesterol reduction and goal achievement with ezetimibe/simvastatin versus atorvastatin or rosuvastatin in patients with diabetes, metabolic syndrome, or neither disease, stratified by National Cholesterol Education Program risk category. Metab Syndr Relat Disord 2009;7:601-610.
  8. Wu H, Perrard XD, Wang Q, Perrard JL, Polsani VR, Jones PH, Smith CW, Ballantyne CM. CD11c expression in adipose tissue and blood and its role in diet-induced obesity. Arterioscler Thromb Vasc Biol 2010;30:186-192.
  9. Chen SN, Cilingiroglu M, Todd J, Lombardi R, Willerson JT, Gotto AM Jr, Ballantyne CM, Marian AJ. Candid ate genetic analysis of plasma high-density lipoprotein-cholesterol and severity of coronary atherosclerosis. BMC Med Genet 2009;10:111.
  10. North KE, Franceschini N, Avery CL, Baird L, Graff M, Leppert M, Chung JH, Zhang J, Hanis C, Boerwinkle E, Volcik KA, Grove ML, Mosley TH, Gu C, Heiss G, Pankow JS, Couper DJ, Ballantyne CM, Linda Kao WH, Weder AB, Cooper RS, Ehret GB, O'Connor AA, Chakravarti A, Hunt SC. Variati on in the checkpoint kinase 2 gene is associated with type 2 diabetes in multiple populations. Acta Diabetol 2009. [Epub ahead of print]
  11. Belalcazar LM, Reboussin DM, Haffner SM, Reeves RS, Schwenke DC, Hoogeveen RC, Pi-Sunyer FX, Ballantyne CM; Look AHEAD (Action for Health in Diabetes) Obesit y, Inflammation, and Thrombosis Research Group. Marine omega-3 fatty acid intake: associations with cardiometabolic risk and response to weight loss intervention in the Look AHEAD (Action for Health in Diabetes) study. Diabetes Care 2010;33:197-199.
  12. Belalcazar LM, Raghavan VA, Ballantyne CM. Statin- induced diabetes: will it change clinical practice? Diabetes Care 2009;32:1941-1943.
  13. Bairey Merz CN, Alberts MJ, Balady GJ, Ballantyne CM, Berra K, Black HR, Blumenthal RS, Davidson MH, Fazio SB, Ferdinand KC, Fine LJ, Fonseca V, Franklin BA, McBride PE, Mensah GA, Merli GJ, O'Gara PT, Thompson PD, Underberg JA; American College of Cardiology Foundation; American Heart Association; American College of Physicians Task Force on Competence and Training (Writing Committee to Develop a Competence and Training Statement on Prevention of Cardiovascular Disease); American Academy of Neurology; American Association of Cardiovascular and Pulmonary Rehabilitation; American College of Preventive Medicine; American Diabetes Association; American Society of Hypertension; Association of Black Cardiologists; National Lipid Association; Preventive Cardiovascular Nurses Association. ACCF/ AHA/ACP 2009 competence and training statement: a curriculum on prevention of cardiovascular disease: a report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Competence and Training (Writing Committee to Develop a Competence and Training Statement on Prevention of Cardiovascular Disease): developed in collaboration with the American Academy of Neurology; American Association of Cardiovascular and Pulmonary Rehabilitation; American College of Preventive Medicine; American College of Sports Medicine; American Diabetes Association; American Society of Hypertension; Association of Black Cardiologists; Centers for Disease Control and Prevention; National Heart, Lung, and Blood Institute; National Lipid Association; and Preventive Cardiovascular Nurses Association. J Am Coll Cardiol 2009;54:1336-1363.
  14. Bairey Merz CN, Alberts MJ, Balady GJ, Ballantyne CM, Berra K, Black HR, Blumenthal RS, Davidson MH, Fazio SB, Ferdinand KC, Fine LJ, Fonseca V, Franklin BA, McBride PE, Mensah GA, Merli GJ, O'Gara PT, Thompson PD, Underberg JA; American Academy of Neurology; American Association of Cardiovascular and Pulmonary Rehabilitation; American College of Preventive Medicine; American College of Sports Medicine; American Diabetes Association; American Society of Hypertension; Association of Black Cardiologists; Centers for Disease Control and Prevention; National Heart, Lung, and Blood Institute; National Lipid Association; Preventive Cardiovascular Nurses Association. ACCF/ AHA/ACP 2009 competence and training statement: a curriculum on prevention of cardiovascular disease: a report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Competence and Training (Writing Committee to Develop a Competence and Training Statement on Prevention of Cardiovascular Disease): developed in collaboration with the American Academy of Neurology; American Association of Cardiovascular and Pulmonary Rehabilitation; American College of Preventive Medicine; American College of Sports Medicine; American Diabetes Association; American Society of Hypertension; Association of Black Cardiologists; Centers for Disease Control and Prevention; National Heart, Lung, and Blood Institute; National Lipid Association; and Preventive Cardiovascular Nurses Association. Circulation 2009;120:e100-e126.
  15. Vasudevan MM, Ballantyne CM. Advan ces in lipid testing and management in patients with diabetes mellitus. Endocr Pract 2009;15:641-652.
  16. Wu H, Ballantyne CM. Inflam mation, adipose tissue, and T cells: what is the "straight skinny" on lean versus fat mice? Circ Res 2009;105:e3-e4.
  17. Shiffman D, Chasman DI, Ballantyne CM, Nambi V, Devlin JJ, Boerwinkle E. Coron ary heart disease risk, aspirin use, and apolipoprotein(a) 4399Met allele in the Atherosclerosis Risk in Communities (ARIC) study. Thromb Haemost 2009;102:179-80.
  18. Robinson JG, Ballantyne CM, Grundy SM, Hsueh WA, Parving HH, Rosen JB, Adewale AJ, Polis AB, Tomassini JE, Tershakovec AM. Lipid-a ltering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study). Am J Cardiol 2009;103:1694-1702.
  19. Nambi V, Kimball KT, Bray PF, Bergeron AL, Johnson SL, Morrisett JD, Chen C, Lin PH, Lumsden AB, Ballantyne CM, Dong JF. Differe nces in responses of platelets to fluid shear stress in patients with peripheral artery disease (PAD) and coronary artery disease (CAD). Platelets 2009;20:199-205.
  20. Wu H, Gower RM, Wang H, Perrard XY, Ma R, Bullard DC, Burns AR, Paul A, Smith CW, Simon SI, Ballantyne CM. Functi onal role of CD11c+ monocytes in atherogenesis associated with hypercholesterolemia. Circulation 2009;119:2708-2717.
  21. Hlatky MA, Greenland P, Arnett DK, Ballantyne CM, Criqui MH, Elkind MS, Go AS, Harrell FE Jr, Hong Y, Howard BV, Howard VJ, Hsue PY, Kramer CM, McConnell JP, Normand SL, O'Donnell CJ, Smith SC Jr, Wilson PW; American Heart Association Expert Panel on Subclinical Atherosclerotic Diseases and Emerging Risk Factors and the Stroke Council. Criteri a for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation 2009;119:2408-2416.
  22. Breslow NE, Lumley T, Ballantyne CM, Chambless LE, Kulich M. Using the whole cohort in the analysis of case-cohort data. Am J Epidemiol 2009;169:1398-1405.
  23. Monda KL, Ballantyne CM, North KE. Longit udinal impact of physical activity on lipid profiles in middle-aged adults: the Atherosclerosis Risk in Communities Study. J Lipid Res 2009;50:1685-1691.
  24. Bang H, Mazumdar M, Newman G, Bomback AS, Ballantyne CM, Jaffe AS, August PA, Kshirsagar AV. Scree ning for kidney disease in vascular patients: SCreening for Occult REnal Disease (SCORED) experience. Nephrol Dial Transplant 2009;24:2452-2457. Inflam matory protein levels and depression screening after coronary stenting predict major adverse coronary events. Biol Res Nurs 2009;11:163-173.
  25. Frazier L, Vaughn WK, Willerson JT, Ballantyne CM, Boerwinkle E.
  26. Goldberg AC, Bays HE, Ballantyne CM, Kelly MT, Buttler SM, Setze CM, Sleep DJ, Stolzenbach JC. Efficac y and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia. Am J Cardiol 2009;103:515-522.
  27. Chen SN, Ballantyne CM, Gotto AM Jr, Marian AJ. The 9p21 susceptibility locus for coronary artery disease and the severity of coronary atherosclerosis. BMC Cardiovasc Disord 2009;9:3.
  28. Nambi V, Ballantyne CM. "Risky business": ten years is not a lifetime. Circulation 2009;119:362-364.
  29. Pearson TA, Ballantyne CM, Veltri E, Shah A, Bird S, Lin J, Rosenberg E, Tershakovec AM. Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy. Am J Cardiol 2009;103:369-374.
  30. NACB LMPG Committee Members, Myers GL, Christenson RH, Cushman M, Ballantyne CM, Cooper GR, Pfeiffer CM, Grundy SM, Labarthe DR, Levy D, Rifai N, Wilson PW. National Academy of Clinical Biochemistry Laboratory Medicine Practice guidelines: emerging biomarkers for primary prevention of cardiovascular disease. Clin Chem 2009;55:378-384.
  31. Nambi V, Hoogeveen RC, Chambless L, Hu Y, Bang H, Coresh J, Ni H, Boerwinkle E, Mosley T, Sharrett R, Folsom AR, Ballantyne CM. Lipopr otein-associated phospholipase A2 and high-sensitivity C-reactive protein improve the stratification of ischemic stroke risk in the Atherosclerosis Risk in Communities (ARIC) study. Stroke 2009;40:376-381.
  32. Yan Y, North KE, Ballantyne CM, Brancati FL, Chambless LE, Franceschini N, Heiss G, Kottgen A, Pankow JS, Selvin E, West SL, Boerwinkle E. Transc ription factor 7-like 2 (TCF7L2) polymorphism and context-specific risk of type 2 diabetes in African American and Caucasian adults: the Atherosclerosis Risk in Communities study. Diabetes 2009;58:285-289.
  33. Otokozawa S, Ai M, Van Himbergen T, Asztalos BF, Tanaka A, Stein EA, Jones PH, Schaefer EJ. Effects of intensive atorvastatin and rosuvastatin treatment on apolipoprotein B-48 and remnant lipoprotein cholesterol levels. Atherosclerosis 2009;205:197-201.
  34. van Himbergen TM, Matthan NR, Resteghini NA, Otokozawa S, Ai M, Stein EA, Jones PH, Schaefer EJ. Comp arison of the effects of maximal dose atorvastatin and rosuvastatin therapy on cholesterol synthesis and absorption markers. J Lipid Res 2009;50:730-739.
  35. Jones PH, Davidson MH, Kashyap ML, Kelly MT, Buttler SM, Setze CM, Sleep DJ, Stolzenbach JC. Efficac y and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study. Atherosclerosis 2009;204:208-215.
  36. Polsani VR, Virani SS, Nambi V. Lipid management: considerations in acute coronary syndrome. Curr Atheroscler Rep 2009;11:149-156.
  37. Virani SS, Alam M, Mendoza CE, Arora H, Ferreira AC, de Marchena E. Clinical significance, angiographic characteristics, and short-term outcomes in 30 patients with early coronary artery graft failure. Neth Heart J 2009;17:13-17.
  38. Divakaran VG, Brown WR, Virani SS. Image s in echocardiography: a freely floating saphenous vein graft. Echocardiography 2009;26:868-869.
  39. Alam M, Simpson L, Virani SS, Cheong B, Loyalka P, Civitello AB. Incidental diagnosis of interrupted aortic arch in a 72-year-old man. Tex Heart Inst J 2009;36:494-495.
  40. Alam M, Virani SS, Simpson L, Williams SB, Wilson JM. Cardia c sarcoidosis: a clinical entity uncommonly recognized. Tex Heart Inst J 2009;36:501-503.
  41. Tchoua U, Gillard BK, Pownall HJ. HDL superphospholipidation enhances key steps in reverse cholesterol transport. Atherosclerosis 2009. [Epub ahead of print]
  42. Gillard BK, Lin HY, Massey JB, Pownall HJ. Apolipoproteins A-I, A-II and E are independently distributed among intracellular and newly secreted HDL of human hepatoma cells. Biochim Biophys Acta 2009;1791:1125-1132.
  43. Rosales C, Gillard BK, Courtney HS, Blanco-Vaca F, Pownall HJ. Apolip oprotein modulation of streptococcal serum opacity factor activity against human plasma high-density lipoproteins. Biochemistry 2009;48:8070-8076.
  44. Ruan H, Pownall HJ. The adipocyte IKK/NFkappaB pathway: a therapeutic target for insulin resistance. Curr Opin Investig Drugs 2009;10:346-352.
  45. Han M, Gillard BK, Courtney HS, Ward K, Rosales C, Khant H, Ludtke SJ, Pownall HJ. Disruption of human plasma high-density lipoproteins by streptococcal serum opacity factor requires labile apolipoprotein A-I. Biochemistry 2009;48:1481-1487.
  46. Massey JB, Pownall HJ, Macha S, Morris J, Tubb MR, Silva RA. Mass spectrometric determination of apolipoprotein molecular stoichiometry in reconstituted high density lipoprotein particles. J Lipid Res 2009;50:1229-1236.
  47. Nambi V. Vascul ar and cardiac ultrasonographers: is it time to use frequencies from the same band-width? J Am Soc Echocardiogr 2009;22:A30.
  48. Nambi V. Inflam mation and cardiovascular risk. Vijay Nambi speaks to Christine Forder, commissioning editor. Future Cardiol 2009;5:121-123.
  49. Wang GJ, Lin YL, Chen CH, Wu XC, Liao JF, Ren J. Cellular Calcium Regulatory Machinery of Vasorelaxation Elicited by Petasin. Clin Exp Pharmacol Physiol 2009. [Epub ahead of print]
  50. Chen CH, Dixon RA, Ke LY, Willerson JT. Vascular progenitor cells in diabetes mellitus: roles of Wnt signaling and negatively charged low-density lipoprotein. Circ Res 2009;104:1038-1040.
  51. Lu J, Yang JH, Burns AR, Chen HH, Tang D, Walterscheid JP, Suzuki S, Yang CY, Sawamura T, Chen CH. Mediation of electronegative low-density lipoprotein signaling by LOX-1: a possible mechanism of endothelial apoptosis. Circ Res 2009;104:619-627.

E-mail this page to a friend